Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких
Аннотация
Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких.
Об авторе
С. Н. Авдеев
ФГУ "НИИ пульмонологии" ФМБА России
Россия
Россия
д. м. н., проф., руководитель клинического отдела
105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел./ факс: (495) 465-52-64.
Список литературы
1. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.
2. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51: 1–16.
3. Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397–412.
4. Zielinski J., MacNee W., Wedzicha J., et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
5. Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467.
6. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.
7. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.goldcopd.org
8. Donaldson G.C., Wedzicha J.A. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–168.
9. Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238.
10. Smeeth L., Thomas S.L., Hall A.J. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–2618.
11. Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
12. Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–115.
13. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.
14. Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest 2000; 118; 193–203.
15. Puhan M.A., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.
16. Woodhead M., Blasi F., Ewig S. et al.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 2005; 26: 1138–1180.
17. O'Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.
18. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
19. Celli B.R., MacNee W.; ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
20. Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
21. Weis N., Almdal T. C-reactive protein – can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88–91.
22. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664–667.
23. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Урал. мед. журн. 2008; 13: 19–24.
24. Wilson R., Jones P., Schaberg T. et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–342.
25. Martinez F., Han M., Flaherty K., Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Exp. Rev. Anti Infect. Ther. 2006; 4: 101–124.
26. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин микробиол. антимикроб. химиотер. 2010; 12 (4): 329–341.
27. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127–1137.
28. Anzueto A., Fisher C.L. Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.
29. Amsden G.W., Baird I.M., Simon S., Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772–777.
30. Andre'Alves M.R., Jardim J.R., Silva R.F. et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J. Bras. Pneumol. 2007; 33: 43–50.
31. Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective. Amer. J. Med. 2004; 117.(9A): 2S–4S.
32. EUCAST Expert rules in antimicrobial susceptibility testing, version 1, April 2008. http://www.EUCAST.org
33. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.
34. Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap. 2006; 19: 11–19.
35. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239–242.
36. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1994; 6: 592–599.
37. Sethi S., Fogarty C., Fulambarker A. A randomized, doubleblind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697–707.
38. Lode H., Eller J., Linnhoff A., Ioanas M. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur. Respir. J. 2004; 24: 947–953.
39. Wilson R., Allerga L., Huchon G. et al. Short-term and longterm outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953–964.
40. Geddes A.M., Klugman K.P., Rolinson G.N. Introduction: historical perspective and development of amoxicillin / clavulanate. Int. J. Antimicrob. Agents 2007; Suppl. 2: S109–S112.
41. McIvor R.A. Antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Can. Fam. Physician. 2009; 55: 15–16, 19–21.
42. Сидоренко С.В., Козлов С.Н. Группа пенициллинов. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии. М.: Боргес; 2002. 47–55.
43. Beghi G., Berni F., Carratu L. et al. Efficacy and tolerability of azithromycin versus amoxicillin clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother 1995; 7: 146–152.
44. Canut A., Martιn'Herrero J.E., Labora A., Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 2007; 60: 605–612.
45. Llor C., Naberan K., Cots J.M. et al. Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch. Bronconeumol. 2006; 42: 175–182.
46. Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator film-coated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.
47. Карпов О.И. Флемоклав Солютаб – новая лекарственная форма амоксициллина / клавуланата в лечении синусита. Клиническая фармакология и терапия 2006; 15 (4): 1–4.
48. Cortvriendt W.R., Verschoor J.S., Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977–979.
49. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: Открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80.
50. Wilson R., Anzueto A., Miravitlles M. et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAES-TRAL methodology. Int. J. COPD 2011; 6: 373–383.
51. Wilson R., Anzueto A., Miravitlles M. et al. Moxifloxacin vs amoxicillin / clavulanic acid in outpatient AECOPD: MAES-TRAL results. Eur. Respir. J. erj00903-2011; published ahead of print December 1, 2011, doi:10.1183/09031936.00090311.
52. White A.J., Gompertz S., Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.
53. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–2236.
Для цитирования:
Авдеев С.Н. Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких. Пульмонология. 2012;(3):109-114. https://doi.org/10.18093/0869-0189-2012-0-3-109-114
For citation:
Avdeev S.N. Current approach to antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2012;(3):109-114. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-3-109-114
Просмотров: 624
Послать статью по эл. почте 